Last reviewed · How we verify

ketamine sedation versus midazolam sedation

Universidad de Colima · Phase 3 active Small molecule

Ketamine acts as an NMDA receptor antagonist, blocking the action of glutamate in the brain.

Ketamine acts as an NMDA receptor antagonist, blocking the action of glutamate in the brain. Used for Sedation for diagnostic or surgical procedures.

At a glance

Generic nameketamine sedation versus midazolam sedation
Also known asketamine sedation
SponsorUniversidad de Colima
Drug classAnesthetic
TargetNMDA receptor
ModalitySmall molecule
Therapeutic areaAnesthesiology
PhasePhase 3

Mechanism of action

This leads to a dissociative effect, reducing consciousness and pain perception. Ketamine's mechanism is complex and not fully understood, but it is thought to involve multiple receptor subtypes and downstream signaling pathways.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: